Natural Capsules Intrinsic Value

NATCAPSUQHealthcareSmall CapNSE

Market cap ₹228 CrEPS ₹2.52

Current market price

₹216.18

+₹14.81 (+7.35%)

NSE · 2 Sept 2026

Closing price

Intrinsic Value Estimate

Based on peer comparison with available Bear / Base / Bull scenarios.

Peer Value

₹746.65

Peer multiples

Final Intrinsic Value

₹746.65

+245.38% vs market

Undervalued

vs Market Price

+245.38%

Undervalued

Valuation range₹672.65 – ₹779.91

Bear
₹672.65Base
₹746.65central estimateBull
₹779.91

Scenario range reflects the peer-multiple distribution.

Natural Capsules Intrinsic Value Analysis

The latest available EOD closing price for Natural Capsules (NATCAPSUQ) is ₹216 per share. Understock's estimated intrinsic value is ₹747 per share. This estimate is 245.4% above that price; the page's comparison band labels the shares undervalued.

The stored classification marks DCF as not applicable, so the displayed estimate uses the peer-based value of ₹747 without a DCF figure. Peer comparison uses 8 matched industry companies and contributing P/B multiples.

For context, available company data reports ROCE of -7.0% and P/E of 85.8×. These metrics describe the business and are not separate intrinsic-value estimates.

How Understock Calculates Intrinsic Value

Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. For this page, the available displayed estimate comes from peer valuation. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.

See Natural Capsules peer valuation · What intrinsic value means

Aggressively investing in capacity expansion. Free cash flow is negative due to heavy growth capex — not business weakness. Peer comparison is more appropriate than DCF.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Natural Capsules Peer Comparison

How this company stacks up against sector peers on valuation and quality metrics.

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Natural Capsules NATCAPSUQ · you	₹228 Cr	85.8×	1.3×	—	-7.7%	-9.1%	2.8%
Sector median	—	33.3×	4.5×	26.1×	15.6%	9.7%	9.6%
Jagsonpal Pharmaceuticals Limited JAGSNPHARM	₹1,566 Cr	36.5×	5.6×	26.1×	15.6%	15.0%	6.7%
Amrutanjan Health Care Limited AMRUTANJAN	₹1,502 Cr	24.5×	3.8×	19.8×	15.6%	11.5%	9.8%
Syncom Formulations (India) Limited SYNCOMF	₹1,402 Cr	16.6×	4.5×	—	27.2%	0.2%	—
Gujarat Kidney And Super Speciality Limited GKSL	₹1,266 Cr	54.7×	4.3×	44.8×	6.1%	18.9%	—
GPT Healthcare Limited GPTHEALTH	₹1,246 Cr	30.1×	4.7×	13.9×	15.7%	8.9%	9.4%
ONE GLOBAL SERVICE PROVIDER LIMITED ONEGLOBAL	₹1,163 Cr	15.7×	63.1×	—	401.3%	0.1%	—
Laxmi Dental Limited LAXMIDENTL	₹1,099 Cr	39.2×	4.7×	26.4×	11.9%	10.4%	19.8%
Sigachi Industries Limited SIGACHI	₹1,041 Cr	40.0×	2.3×	—	5.8%	0.1%	—

Peer comparison verdict

Natural trades at a premium to sector peers on P/E (85.8× vs median 33.3×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.

Business quality

Valuation

P/E ratio

85.8×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

-7.7%

ROCE

-7.0%

ROA

—

Growth

Revenue CAGR (3yr)

2.8%

EPS CAGR (3yr)

NaN%

Efficiency

Asset turnover

—

FCF yield

-0.3%

Dividend yield

—

Liquidity & Solvency

Debt / Equity

0.43×

Debt / EBITDA

—

Interest coverage

—

Current ratio

1.03×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Is the business financially healthy?

Two structured frameworks that go beyond a single number to assess financial strength.

Altman Z-Score

Predicts likelihood of financial distress. Above 2.99 = safe zone; 1.81–2.99 = grey zone; below 1.81 = distress.

1.00

Distress zone

0 (distress)2.99 (safe)5+

Piotroski F-Score

4 / 9 — Moderate

Nine binary checks across profitability, leverage/liquidity, and operating efficiency. 7+ = financially strong; 4–6 = average; 0–3 = weak signals.

Profitability (1–4)

Leverage (5–7)

Efficiency (8–9)

Positive net income

Positive operating cash flow

Improving return on assets

Cash flow exceeds net income

Debt ratio reduced

Improving current ratio

No equity dilution

Improving gross margin

Improving asset turnover

Calculated from annual report data sourced via BSE/NSE filings. For precise figures refer to BSE/NSE filings.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹187 Cr

Net profit

−₹17 Cr

Operating margin

—

Net margin

-9.1%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

₹10.92 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

-₹0.61 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹96 Cr

Equity

₹222 Cr

Debt / Equity

0.43×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

50.9%

-0.1 pp QoQ

FII

0.0%

DII

0.0%

Retail

49.1%

Trend over time (%)

Quarterly data

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Change (YoY)
Promoter	56.6%	56.6%	56.6%	56.6%	51.6%	51.1%	51.2%	51.3%	51.3%	51.3%	51.0%	50.9%	-0.3 ppYoY
FII (Foreign)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0 ppYoY
DII (Domestic)	1.3%	1.3%	1.3%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0 ppYoY
Retail	42.1%	42.1%	42.1%	43.3%	48.4%	48.9%	48.8%	48.8%	48.7%	48.7%	49.0%	49.1%	+0.3 ppYoY

Signals from the trend

📉

PromoterDown 5.6pp — worth monitoring for further declines

➡️

FIIStable

📉

DIINet sellers (1.3pp) — domestic funds are reducing

Overall cautious — promoter selling warrant monitoring.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.